NCT07241182 Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy
| NCT ID | NCT07241182 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tri-Service General Hospital (TSGH) |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-24 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-11-24 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.
Eligibility Criteria
Inclusion Criteria: * Pathologically and radio-graphically diagnosed lung cancer * Age greater than 18 years * Received platinum-based chemotherapy * Life expectancy of six months or longer Exclusion Criteria: * Inability to comply with timely supplementation administration. * Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function * Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days. * Currently receiving hormone therapy. * Major cardiac disease or arrhythmia severe enough that the attending physician considers the patient unsuitable for trial participation. * Major neuropathy. * Patients with currently active acute infections. * Patients with known allergies/allergic reactions to the investigational product or any components in their formulations. * Patients currently taking supplements containing Antrodia camphorata extract.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07241182 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07241182 currently recruiting?
Yes, NCT07241182 is actively recruiting participants. Contact the research team at doc10376@gmail.com for enrollment information.
Where is the NCT07241182 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07241182 clinical trial?
NCT07241182 is sponsored by Tri-Service General Hospital (TSGH). The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.